Lisen Imprinting Diagnostics Co. Ltd. (LisenID) is a biotechnology company specializing in molecular pathology diagnosis, founded in Delaware, USA. Lisen is at the forefront of epigenetics research by pioneering the development of early stage cancer detection using epigenetic imprinting alteration biomarkers. Our novel epigenetic imprinting platform uses precision biomarkers for diagnosing cancers early. We have 8500+ clinical cases that evidence best-in-class sensitivity and specificity across 12 cancer types. Our US lab is located at the Delaware Innovations Space, a state-of-the-art bioscience facility.
Fully US-owned and operated company
Registered in Delaware US 2016